3 min read
CIPN Keeps Failing in the Clinic. The Preclinical Package May Be Why.
Chemotherapy induced peripheral neuropathy remains one of the most underserved symptoms in oncology supportive care....
Insights on increasing the translational value of your preclinical development program.
Jun 9, 2026by MD Biosciences
Chemotherapy induced peripheral neuropathy remains one of the most underserved symptoms in oncology supportive care....
Jun 2, 2026by MD Biosciences
Chronic wounds in diabetic patients are one of the costliest quietly growing burdens in medicine. Roughly 15 to 25...
May 26, 2026by MD Biosciences
Stroke remains one of the highest attrition areas in drug development. Despite decades of preclinical programs showing...
May 19, 2026by MD Biosciences
Biomarkers have become the connective tissue of modern drug development. They anchor mechanism of action claims,...
May 12, 2026by MD Biosciences
The attrition rate for analgesic compounds remains stubbornly high. By some estimates, fewer than 2% of preclinical...